Berman Tabacco Announces Investigation of Corcept Therapeutics Incorporated (NASDAQ: CORT) Concerning FDA New Drug Application
BOSTON, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Berman Tabacco, a national law firm representing investors, announces that it is investigating potential securities law violations by Corcept Therapeutics Incorporated (Nasdaq: CORT) (“Corcept” or the “Company”), a company based in Redwood City, California.
About the Investigation
On December 31, 2025, Corcept issued a press release announcing that “U.S. Food and Drug Administration (FDA or the Agency) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.” The press release stated, among other things, “We are surprised and disappointed by this outcome.” Corcept common share fell $35.40 per share to close at $34.80 per share on December 31, 2025.
On January 30, 2026, Reuters reported that “shares of Corcept Therapeutics fell 16% on Friday after a corrected ‘complete response letter’ from the U.S. Food and Drug Administration showed the agency had warned the company ‘on several occasions’ not to submit its drug application.”
Contact
If you have information concerning this investigation or if you sustained significant losses from your transactions in Corcept securities, please contact us here: Contact | Berman Tabacco. You may also reach out to us for more information at 800-516-9926 or law@bermantabacco.com.
About Berman Tabacco
Since 1982, our firm has prosecuted hundreds of securities cases on behalf of investors. The firm and its attorneys have been recognized for their work on behalf of plaintiffs, including by Benchmark Litigation, which ranked the firm as a Top Plaintiffs’ Firm and as Highly Recommended. Chambers USA recognized the firm as a leading securities litigation firm in its Securities Litigation–Mainly Plaintiff category. The Legal 500 has also ranked the firm as recommended in securities litigation. The firm has offices in Boston, Massachusetts and San Francisco, California.
This notice may constitute attorney advertising.
Past results do not guarantee future outcomes.
Berman Tabacco
Jay Eng, Esq.
One Liberty Square
Boston, Massachusetts
(800) 516-9926
Email: law@bermantabacco.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
